PHGE Rasio cepet BiomX Inc

BiomX Inc. (PHGE) relies on Israeli laboratories for phage development, delegating drug production to external CDMO partners to minimize operational disruptions. The delivery of biomaterials is maintained under a strict temperature regime, ensuring the integrity of the preparations. The price history on GURU.Markets with the 0.23 indicator confirms the business's independence from market cycles, where growth is driven by clinical trial successes and the launch of new products.

This metric assesses the ability of BiomX Inc. to instantaneously settle short-term liabilities using its most liquid assets, excluding hard-to-sell inventories. For BiomX Inc., the final quick ratio is critically important, as it reflects the financial cushion amid high capital burn during the development of experimental phage therapy.